Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Wilms Tumor 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Histiocytosis, Langerhans-Cell 1Hepatoblastoma 1Glioma 1Ependymoma 1Central Nervous System Neoplasms 1

Interventions

pembrolizumab 74Cyclophosphamide 50Cisplatin 46Nivolumab 36Radiotherapy 33Paclitaxel 33Carboplatin 31Gemcitabine 30Docetaxel 27Dexamethasone 24atezolizumab 23Doxorubicin 21Bevacizumab 21Etoposide 20Blood Specimen Collection 20Vincristine 18Magnetic Resonance Spectroscopy 18Leucovorin 18Lenalidomide 18Fluorouracil 18fludarabine 17Rituximab 17Radiosurgery 17Surveys and Questionnaires 16Oxaliplatin 16Cytarabine 16Radiation 15Ipilimumab 15palbociclib 14durvalumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × LY3023414 × 90 days × Clear all
NCT03213678 2026-04-21

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Completed
18 enrolled 12 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡